ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease

Alzheimer’s disease (AD) is an age-related neurodegenerative disease that affects 50 million people worldwide, with 10 million new cases occurring each year. The emotional and economic impacts of AD on patients and families are devastating. Approved treatments confer modest improvement in symptoms,...

Cijeli opis

Bibliografski detalji

Glavni autori:	Grant A. Krafft, Jasna Jerecic, Eric Siemers, Erika N. Cline
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2022-04-01
Serija:	Frontiers in Neuroscience
Teme:	Alzheimer’s disease immunotherapy oligomer-selective therapeutic antibody AβO = amyloid beta oligomer synaptic plasticity
Online pristup:	https://www.frontiersin.org/articles/10.3389/fnins.2022.848215/full
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!